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1. Introduction 
Myelodysplastic syndromes are a heterogeneous group of clonal bone marrow disorders, 
which are considered to be cancers and have a tendency to transform into acute myeloid 
leukemia. MDS are characterised by the underproduction of normal blood cells. Disease-
induced cytopenias result infections and bleeding complications.  
The diverse pathobiology of the disease is manifested by a varied clinical course, with some 
patients having more indolent disease and longer life expectancy, and others presenting 
with aggressive variants that rapidly progress to AML. 
The frequency of the disease is the highest in the elderly. Number of diagnoses has 
increased in the past decade as a consequence of the increased recognition, and the aging of 
the population.  
Prognosis is influenced by the age and co-morbidities of the patient and also by the 
cytogenetic abnormalities. 
Risk stratification is based on the number of myeloblast in the bone marrow, the number of 
cytopenias and the cytogenetic abnormalities. The most widely used prognostic systems are 
the International Prognostic Scoring System (IPSS) and the WHO classification-based 
Prognostic Scoring System (WPSS). The latter system incorporates transfusion burden as 
well (Greenberg, 1998). 
From the standpoint of both disease biology and prognosis, it is important to distinguish 
primary MDS from therapy-related MDS; the latter is closely related to therapy-related 
AML and develops in the setting of prior exposure to chemotherapy (eg, alkylating agents, 
topoisomerase II inhibitors), radiotherapy, radiation accidents, benzene, or other toxins and 
is prognostically worse than primary MDS. Response to therapy is highly worse in this 
group of patients (Tefferi, 2010; Graubert, 2010). 
Treatment of MDS in the past was restricted to supplementation of the missing cell type 
thus relieving the patient’s symptoms. Advances over the last decade have given a 
multitude of treatment options. Therapeutic options now exist that not only reduce disease-
related symptoms, improve quality of life, but alter the natural history of the disease as well.  
2. Epidemiology 
The incidence of newly diagnosed MDS exceeds 10.000 cases in the US annually. MDS are 
the most common in older patients. At the time of diagnosis, 86 % of patients are 60 years or 
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older. The incidence of MDS rises from 3,4 cases per 100.000 in the general population to 15 
to 50 cases per 100.000 in people older than 75 years (Giralt et al., 2011).  
The incidence and prevalence of MDS has increased significantly over the past 20 years as a 
result of increasing longevity of the population and increasing physician awareness 
(Goldberg et al., 2010). 
Among patients diagnosed with MDS, 14% have been treated for other primary tumors 
prior to diagnosis (Ma et al., 2007; Sekeres, 2011a). 
3. Survival 
Patient outcomes vary depending on disease presentation. Among untreated patients with 
MDS, median survival varies from 5,7 years in low-risk patients to 0,4 years in patients with 
high risk disease. For patients with del(5q) as the only chromosomal aberration, medial 
survival is 73 months compared to 19,3 months for patients with more than one aberration. 
Transfusion need at diagnosis is the most independent parameter for survival, with 
transfusion-dependent patients having a median survival of 39 months versus 97 months for 
transfusion-independent patients. 
4. Staging system, risk stratification 
The IPSS was the first system to stratify patients according to their risk of death or evolution 
to AML. It is based on percentage of bone marrow blasts, cytogenetic abnormalities, and 
number of cytopenias. However, the IPSS does not consider the severity of anaemia and  
 
Factors for determining IPSS score 
 Score value 
Prognostic 
variable 
0 0.5 1.0 1.5 2.0 
Blasts in 
marrow 
(%) 
< 5 5-10 - 11-20 21-30 
Karyotype good Intermediate Poor - - 
Cytopenias 0/1 2/3 - - - 
Good = normal, -Y, del(5q), del(20q);  
poor = complex (3 abnormalities) or chromosome 7 anomalies;  
intermediate = other abnormalities. 
Risk of transformation and median survival 
Risk Total score Progression to AML 
Without therapy 
(year) 
Median survival 
Without therapy (years) 
Low 0 9.4 5.7 
Int-1 0.5-1.0 3.3 3.5 
Int-2 1.5-2.0 1.1 1.2 
High ≥ 2.5 0.2 0.4 
Int-1 = intermediate-1, Int-2 = intermediate-2 
Table 1. The International Prognostic Score System (IPSS) for MDS 
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transfusion requirement, which are definitely associated with reduced survival in MDS. The 
newer WPSS has five prognostic groups with distinct survival times and probabilities of 
progression to AML. While the IPSS is limited to newly diagnosed patients with MDS, the 
WPSS can be applied at any time during the disease course. It has been shown that the 
WPSS improves survival prediction and identifies patients with very low-risk disease who 
may achieve long-term survival. 
 
Variable 0 1 2 3  
WHO 
category 
RA, RARS, 5q- RCMD, 
RCMD-RS 
RAEB-1 RAEB-2  
Karyotype Good Intermediate Poor —  
Transfusion 
requirement 
No Regular — —  
Abbreviations: RA = refractory anaemia; RAEB-1 = refractory anaemia with excess blasts type 1; RAEB-
2 = refractory anaemia with excess blasts type 2; RARS = refractory anaemia with ringed sideroblasts; 
RCMD = refractory cytopenia with multilineage dysplasia; RCMD-RS = refractory cytopenia with 
multilineage dyslasia and ringed sideroblasts;  
Table 2. The WHO Classification-Based Prognostic Score System (WPSS) for MDS 
5. New prognostic factors 
Conventional metaphase cytogenetic analysis is limited by the sensitivity of the assay, and 
therefore new technologies are being applied in MDS to detect genomic alterations. One of 
these approaches has been the use of single-nucleotide polymorphism arrays (SNP-A). 
Using SNP-A, several candidate genes have been described recently, and include c-CBL 
(encodes an E3 ubiquitin ligase that inhibits tyrosine kinase signalling) (Sanada et al., 
2008), ASXL1, and TET-2 (which are significant because they may have a role in the 
control of epigenetic alterations in MDS.) (Boultwood et al., 2010; Jankowska et al., 2009; 
Garcia-Manero, 2010). 
6. Treatment goals and options 
The goals of treatment for patients with MDS are to prolong overall survival, reduce 
transfusion burden, and improve their quality of life (Scott, 2008). 
Treatment options for individual patients with MDS depend on the disease classification, 
prognostic stage and the age and health status of the patient. 
For patients with lower risk disease (IPSS: low- or intermediate-1-risk) options include 
lenalidomide, erythropoietin-stimulating agents and immunosuppressive therapy, as well 
as hypomethylating agents (azacitidine and decitabine). For patients with del(5q) 
syndrome lenalidomide is the treatment of choice. For patients with higher risk (IPSS: 
intermediate-2-, or high-risk), intensive therapy with allogeneic stem cell transplantation 
(alloSCT) remains the only potentially curative treatment option (Sekeres, 2009; Mufti & 
Chen, 2008).  
For the majority of patients who are not candidates for alloSCT, treatment options include 
azacitidine or decitabine, clinical trials, or supportive care. 
In addition, all patients receiving active therapy should receive continuous supportive care. 
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7. Considerations regarding to select the appropriate treatment options  
Treatment consideration must take into account many factors, including the pathologic 
diagnosis, the prognosis based on the IPSS or WPSS, the unique disease features in that 
particular patient, feasibility of performing a clinical trial, the appropriateness of a bone 
marrow transplantation, and the philosophy of the patient and the family concerning his or 
her care (Malcovati & Nimer, 2008; Barzi & Sekeres, 2010; Greenberg, 2010).  
In addition, if the patient has a secondary MDS, tolerability of therapy is probably worse 
because of previous exposure to DNA-damaging agents. 
Older age per se has a negative impact on survival of MDS patients, in particular of those 
with low-risk disease. However, age affects the survival of high-risk patients indirectly as 
well, by limiting their eligibility to intensive treatments. In addition, aging is associated with 
an increasingly high risk of developing co-morbidity. 
Co-morbidities have a significant impact on the outcome of patients with MDS. Risk 
stratification should also have to include the assessment of co-morbidities of the MDS 
patients.  
One of the most important areas of research is the identification of biomarkers of response to 
therapy (Garcia-Manero, 2010). A critical example is the discovery by List et al. of the 
relationship between the presence of a chromosome 5 alterations and response to 
lenalidomide (List et al., 2006), which resulted in the development of targeted approaches to 
these patients, as well as an entirely new field of research with the discovery of RPS14 as a 
critical gene in 5q31 (Ebert et al, 2008). Predictors of responsiveness to immunosuppressive 
therapy are younger age, HLA-DR15 type, the interval between first transfusion and starting 
of immunosuppressive treatment. (Sloand et al., 2008; Barrett et al., 2006). 
8. Patient selection 
The selection of an adequate treatment option has to be preceded by thorough 
consideration, that have to take account of several points of view. The proper patient 
selection is the key element of successful treatment. 
There is a significant role of the patient’s intent beyond the severity of the illness in the 
embracement of the most appropriate treatment option in case of a given patient. Patient has 
to be committed to the treatment as he or she takes the risk of the adverse effects of the 
treatment, and also he or she undertakes the inconveniences of a long-term treatment 
process.  
9. Treatment modalities in MDS 
Taking into account the above mentioned aspects, there are several possibilities to choose: 
observation, supportive care, iron chelation, erythropoiesis-stimulating agents (EPOs), 
immunosuppressive treatment, intensive chemotherapy, and also disease-altering options: 
hypomethylating agents, lenalidomide, alloSCT, as well as entrance in a clinical trial (Barzi 
& Sekeres, 2010).  
9.1 Observation 
Many patients, especially those who are older and frail, benefit from a period of observation 
before any discussion about the need for therapy is made. Treatment should be reserved 
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only if there are symptoms resulting from anaemia or other cytopenias or perhaps 
presymptomatic anaemia or severe thrombocytopenia. 
9.2 Supportive therapy 
Supportive care includes transfusion of red blood cells and platelets to minimize 
complication of cytopenias and to improve quality of life, as well as antibiotics to treat 
infections. 
Patients with symptomatic anaemia should receive transfusion to relieve their symptoms. 
Platelet transfusion must be given in case of severe thrombocytopenia which cause bleeding. 
9.3 Erythropoiesis-stimulating agents 
Once an MDS patient become transfusion-dependent, erythropoietin-stimulating agents 
(ESAs) can be considered. These include epoietin (Eprex) and darbopoietin alfa (Aranesp). 
The clinical practice guideline of the American Society of Haematology suggests to use 
epoietin and darbepoietin in adults with lower risk MDS without chemotherapy. 
Erythropoiesis stimulating agents are used by more than 50% of patients (Sekeres, 2011a,). 
Recently ESAs are increasingly used to treat anaemia of lower risk MDS, even before RBC 
transfusion requirement. Early introduction of ESA in lower risk MDS, may help to better 
avoid the consequences of anaemia and also to delay the need for RBC transfusions, 
hypothetically by slowing the disease course (Park et al., 2010). 
EPOs are recommended particularly for those with low serum EPO level. Serum 
erythropoietin (EPO) level  500 mU/ml may respond to EPO if relatively high doses are 
administered. The EPO dose required is 40.000-60.000 units 1-3 times a week 
subcutaneously. Erythroid response occur within 6 to 8 weeks of treatment (Hellström-
Lindberg E, 2003; Jädersten et al., 2008). 
In a phase 3 prospective randomized trial the efficacy and long-term safety of EPO with or 
without granulocyte colony-stimulating factor plus supportive care was evaluated versus 
supportive care alone for the treatment of anaemic patients with lower-risk MDS (Greenberg 
et al., 2009). In comparison with supportive care alone, patients receiving EPO with or 
without granulocyte colony-stimulating factor plus supportive care had improved erythroid 
responses, similar survival, and incidence of acute myeloid leukemia transformation. 
Responding patients had significantly lower serum EPO levels (45% vs 5% responses for 
levels < 200 mU/mL vs ≥ 200 mU/mL). (Rizzo et al., 2010).  
9.4 Iron chelation therapy 
Many MDS patients are dependent on red blood cell (RBC) transfusions for symptomatic 
management of refractory anaemia. Iron overload ensues when the iron acquired from 
transfused RBCs exceeds body storage capacity, thereby raising the risk for end organ 
damage (List, 2010).  
The use of iron chelation in myelodysplastic syndrome (MDS) has generated much 
controversy recently (Steensma, 2009a). Transfusion dependency is associated with 
shortened overall survival and leukemia-free survival in MDS. The major question is 
whether this effect is mediated by transfusional iron overload itself or if need for red cell 
transfusion is simply a marker of disease severity (Malcovati et al., 2005). 
Averting cardiac dysfunction in low-grade MDS patients who have sufficient longevity to 
experience deleterious cardiac effects of iron overload has been the major argument in favor 
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of iron chelation. However, the role of iron chelation therapy in MDS remains controversial. 
Although there is significant evidence showing the adverse impact of transfusion 
dependency on survival in MDS, direct evidence linking tissue iron overload to poor 
survival or in particular to cardiac dysfunction is lacking.  
Present evidence suggesting that the major benefit of iron chelation in MDS is not likely to 
come from reduction in cardiac and other end organ damage due to tissue iron overload, 
but from a potential favorable impact on 3 other outcomes namely: lowering infection risk, 
improving the outcome of allogeneic hematopoietic stem cell transplantation, and delaying 
leukemic transformation. These outcomes have particular relevance for patients with higher 
grades of MDS (Pullarkat, 2009).  
Application of recent advances in the treatment of MDS can reduce or eliminate the need for 
transfusions, thus minimizing the risk of iron overload.  
Iron chelation strategies include oral agents such as deferasirox (Exjade, Novartis), 
deferiprone (Ferriprox, Apotex Europe BV,) and parenteral administration of deferoxamine 
(Desferal, Novartis).  
Considering the short survival of patients with MDS, the benefit of iron chelation is 
debatable. This procedure is advised for those who have received more than 25 units of 
packed red blood cells. 
Unfortunately, iron chelation is expensive and, to date, has not shown a clear survival 
benefit in the MDS population. 
9.5 Hypomethylating agents 
MDS pathophysiology is complex, and still not completely understood. Structural 
alterations in DNA play a role in the pathogenesis of disease. Epigenetic changes in the form 
of modifications to the transcriptional capacity of the cell via processes, such as DNA 
methylation can also alter gene expression impacting disease biology. As such, 
hypermethylation of the promoters of certain tumor suppression genes is prevalent in MDS 
and secondary AML, and it is postulated that the DNA hypomethylation may result in the 
reactivation of silenced genes, restoring their cancer-suppressing functions, and inducing 
cellular differentiation providing a biologically rational therapeutic target for MDS.  
Currently, both FDA- (U.S. Food and Drug Administration) approved hypomethylating 
agents (azacitidine and decitabine) have shown good clinical responses in patients with 
MDS. In the last two decades the use of epigenetic therapy has gained popularity, given its 
favorable side effect profile and its potential to improve survival. 
9.5.1 Azacitidine (5-azacytidine; Vidaza) 
Azacitidine (5-azacytidine; Vidaza; Pharmion Corporation) for injectable suspension 
received regular approval by the FDA for the treatment of all subtypes of MDS in 2004. It 
was the first agent that has been reported to prolong survival in MDS patients. 
9.5.1.1 Mechanism of action 
Azacitidine is a nucleosid analog that incorporates into RNA and requires the activity of 
ribonucleotide reductase to be incorporated to DNA. The incorporation of azacitidine into 
DNA leads to inhibition of DNA methyltransferase (DNMT) which has been known to 
hypermethylate cytosine residues at cytosine-guanine repeat sequences. By reducing the 
quantity of hypermethylated DNA produced, azacitidine can serve to limit the proliferation 
www.intechopen.com
 
Treatment Options in Myelodysplastic Syndromes 
 
295 
of malignant cells, while allowing an increased proportion of normal cells to differentiate. 
Although azacitidine falls into the category of hypomethylating agents, its mechanism of 
action is likely multifactorial (Yang et al, 2010).  
9.5.1.2 Identification patients for azacitidine treatment 
Azacitidine was approved by the US FDA on the basis of CALGB (Cancer and Leukemia 
Group B) 9221. This randomized trial compared azacitidine with best supportive care 
(BSC) targeting high-intermediate and high-risk disease and including low-intermediate 
risk patients with ongoing complications of cytopenias. The results demonstrated 
superiority of azacitidine over BSC in terms of quality of life, reduced transfusion needs, 
and delayed time to AML transformation or death for higher risk patients (Kurtin & 
Demakos. 2010,). 
It was the AZA-001 trial (the second randomized trial, which was conducted to define 
whether an endpoint not of response but overall survival (OS) could be met with 
hypomethylation therapy) which revealed that azacitidine significantly improved OS 
compared to that of the conventionally treated patients (either BSC, low-dose cytosine-
arabinoside, or intensive induction chemotherapy). There was no particular „winner” 
regarding the different subsets of patients treated. Response benefit was distributed fairly 
evenly across various subgroups of patients. This was true across younger and older 
patients, gender, performance status, FAB subtype, WPSS, IPSS score, cytogenetic risk 
category, and bone marrow blasts rate (Edlin et al., 2010). 
The rate of complete response (CR) was rather low in the AZA-001 trials (17 % in the 
azacitidine arm). The low CR rate provides compelling data against oncology dogma that 
achievement of CR is required for survival benefit. Indeed, a retrospective subset analysis 
examined the survival impact of azacitidine excluding patients who achieved CR. One-year 
survival rates were superior for azacitidine treatment versus conventional treatment (68% vs 
56 %, P= 0,015), thus achieving a CR is no longer a sufficient predictor for a therapy’s ability 
to extend survival and alter course of MDS. 
Critical to the success of azacitidine is the selection of appropriate patients. Higher risk MDS 
patients who are of reasonable performance status with adequate organ function are 
excellent candidates and also those lower risk patients who are transfusion dependent or 
have severe cytopenias. 
9.5.1.3 Side effects 
Adverse events are inevitably encountered. Haematological toxicities are common, 
particularly in the first one to two cycles. Infections have occured in 50 % of azacitidine-
treated patients in AZA-001 trial. 58 % of patients experienced thrombocytopenia and/or 
neutropenia.  
Common other adverse effects are gastrointestinal (vomiting, diarrhoea, anorexia), fevers, 
rigors, arthralgia, headache, and dizziness (San Miguel Amigo, 2011). 
9.5.1.4 Dosage and administration 
For azacitidine the most appropriate dosing schedule is 75 mg/m2 subcutaneously for 7 
days, every 4 weeks. It is also an important issue to keep on treatment for at least at six 
cycles. In case of the absence of unacceptable toxicity or the evidence of disease progression, 
therapy should be continued for the maintenance of the response. 
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9.5.1.5 Azacitidine for maintenance of complete remission after chemotherapy 
A Phase II prospective study was performed to assess the feasibility and efficacy of 
maintenance azacitidine for older patients with high-risk MDS in CR after induction 
chemotherapy. Sixty patients were enrolled and treated by standard induction 
chemotherapy. Patients that reached CR started maintenance therapy with subcutaneous 
azacitidine, 5/28 days until relapse. Median overall survival was 20 months. A dose of 60 
mg/m(2) was well tolerated. Grade III-IV thrombocytopenia and neutropenia occurred after 
9.5 and 30% of the cycles, respectively, while haemoglobin levels increased during 
treatment. azacitidine treatment is safe, feasible and may be of benefit in a subset of patients 
(Grövdal et al., 2010). 
9.5.2 Decitabine (dezocitidine, Dacogen, SuperGen, Inc., Dublin) 
Decitabine is another hypomethylating agent approved by the US FDA in 2006 for the 
treatment of de novo and secondary MDS (for intermediate-1-, intermediate-2-, and high-risk 
MDS patients). It has been studied predominantly in higher-risk MDS patients. 
The FDA approval was based on the randomized phase III trial (EORTC 06011) versus BSC 
using the European administration schedule. Decitabine-treated patients had improved 
quality of life, and reduced transfusion needs. Although there was a delayed time to AML 
transformation or death, this trial failed to shown any survival benefit for decitabine arm. 
The relatively short duration of therapy administered was the main limitation of the study 
design which may negatively affected outcomes (Garcia et al., 2010,).  
Concerning studies with hypomethylating agents the best available evidence and consensus 
is that patients benefiting from therapy should continue treatment until progression or 
unacceptable toxicity. 
The toxicity profile of the two AZA nucleotides is similar.  
While the haematological response rates to both hypomethylating agents are similar, the 
survival advantage demonstrated by the FDA-approved dose schedule of azacitidine 
compared with conventional care, as well as the absence of such a survival advantage in 
response to the FDA-approved dose schedule of decitabine in two randomized studies, 
makes azacitidine the drug of choice for AZA nucleoside-naive, high-risk MDS patients. 
Perhaps the better-tolerated North American decitabine schedule would lead to similar 
survival advantage.  
A comparative trial of azacitidine versus decitabine recently opened to accrual (http:// 
www.ClinicalTrials.gov; identifier: CT01011283). Unfortunately, the trial is designed with a 
primary endpoint of early response at 6 months and is not powered to examine the more 
relevant question of OS. (Blum, 2010) 
9.5.2.1 Dosage and administration of decitabine 
European schedule is 15 mg/m2 intravenously over 3 hours, every 8 hours for 3 days, 
repeated every 6 weeks Kantarjian et al., 2006). In North America, the typical schedule is 20 
mg/m2 intravenously over 1 hour daily for 5 days, repeated every 4 weeks, based on 
promising high CR results of up to 39% in a single center (Kantarjian et al., 2007). A 
multicenter study of 99 patients with MDS using the same regimen, The Alternative Dosing 
for Outpatient Treatment (ADOPT) trial, showed a CR rate of 17%, with an overall response 
rate of 51% (Steensma et al., 2009b). The main point of administration is the number of 
cycles. The better OS results of azacitidine may be the consequence of the higher number of 
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cycles. In the EORTC 06011 study the median number of cycles per patient was four, and 
40% received two or fewer cycles. By comparison, the median number of cycles of AZA 
given in AZA-001 was nine. 
9.6 Lenalidomide 
Lenalidomide is an immunomodulatory drug that is FDA approved for lower risk patients 
with transfusion-dependent anaemia and an interstitial deletion of the long arm of 
chromosome 5 [del(5q)]. The approval was based on high rates of prolonged transfusion 
independence and complete cytogenetic response (Ximeri et al., 2010). 
Treatment with a 10 mg daily dose for 21 days in every 4 weeks results transfusion 
independence in 67 % of patients with del(5q). Lenalidomide treatment does not increase 
risk of AML progression according to the preliminary result of MDS-004 study. It was a 
significant concern in Europe, preventing approval of the drug. Despite the frequent need of 
dose reduction due to myelosuppression, the starting dose of lenalidomide is suggested to 
be 10 mg (Sekeres et al., 2008). 
Though lenalidomide is approved by FDA for del(5q) lower risk subset of MDS patients, it 
is reasonable to consider lenalidomide as frontline treatment in the few higher risk patients 
with MDS who have both isolated del(5q) and platelet count  100.000/µL (Kurtin & 
Demakos,  2010).  
In case of patients with lower risk and without del(5q) the ratio of patients reached 
transfusion independence was much lower and response duration was much shorter than 
that of patients with del(5q). Cytogenetic improvement was also inferior to that observed in 
the del(5q) patients. (Komrokji & List, 2010;, List et al., 2006). 
9.6.1 Mechanism of action 
The drug may have different mechanism of activity, depending on the disease type.  
In del(5q), lenalidomide suppresses the malignant clone, but in non-del(5q) it appears to 
promote erythropoiesis.  
There is now a better understanding of the mechanism of the karyotype-dependent drug 
action. In del(5q) patients, lenalidomide suppresses the clone by inhibiting the nuclear 
sequestration of the haplodeficient cell cycle regulatory protein cdc25c, thereby promoting 
selective G2 arrest and apoptosis (Wei et al., 2009). In non-del(5q) patients, lenalidomide 
enhances erythropoietin receptor signaling. 
9.6.2 Combination treatment 
The addition of lenalidomide to azacitidine may provide additional clinical benefit over e 
monotherapy. 
A recent Phase I trial testing the lenalidomide and azacitidine combination yielded 
encouraging results. In this study, 18 higher-risk MDS patients were treated with the 
combination for seven cycles, after which lenalidomide was discontinued in eight patients 
who achieved a complete response, with azacitidine monotherapy continuing until disease 
progression. Three patients who relapsed on monotherapy with excess blasts at 12, 19, and 
24 months, in whom lenalidomide was then resumed in combination with azacitidine. Each 
patient, one with normal cytogenetics at relapse; one with a 18 abnormality; and one with 
del(4q25), recaptured a complete response that was sustained for 5, 7, and 7+ months. 
The addition of lenalidomide to azacitidine provides additional clinical benefit over 
azacitidine monotherapy. (Sekeres et al., 2011b) 
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9.7 Immunosuppressive treatment 
An activated immune system has been observed in patients with myelodysplastic syndrome 
but its exact contribution to disease development and control is not fully clarified. On the 
one hand an activated and skewed T-cell repertoire has been reported, but on the other 
hand, decreased natural killer cell function has been found. Immune activation could reflect 
undesired autoimmune reactions against normal hematopoietic precursor cells as well as 
effective immune-surveillance against dysplastic clones (Chamuleau et al., 2009). 
Autoreactive T-cell clones have a role in the apoptosis in the bone marrow of MDS, mainly 
in patients with hypocellular bone marrow. Immunosuppressive agents such as 
cyclosporine A (CsA)and anti-thymocyte globulin (ATG), or combination of the two agents 
can improve cytopenia and can reduce transfusion need in a subset of MDS patients. The 
anti-TNF agent etanercept can also be applied in combination with ATG. (Deeg et al., 2004). 
Responses to immunosuppressive therapy in MDS remain among the most durable (and 
perplexing) of all available therapies in the disease. Typically, equine ATG is given at 40 
mg/kg intravenously for four consecutive days, in conjunction with methylprednisone and 
CsA. Initial reports of its use demonstrated achievement of transfusion independence in 21 
of 61 (34%) of patients. More importantly, the probability of continued transfusion 
independence after 5 years was 76%. However, the toxicity of the regimen has led to 
considerable apprehension in its use.  
Most ATG studies in MDS have been single center experiences, and several reports in 
unselected patients have demonstrated lower response rates and significant toxicity with the 
regimen. Clearly, judicious patient selection for the therapy is critical for its success and 
productive implementation. Helpful guidance for the use of ATG in MDS was recently 
published. Outcomes for patients with MDS who were given equine ATG (with or without 
CsA) in sequential protocols at the National Heart, Lung, and Blood Institute between 1971 
and 2003 were described. For 129 ATG-treated patients, 39 patients (30%) responded; 9% 
had CR. Serious infusion-related toxicities were infrequent, but meaningful because 9% of 
patients required temporary intensive care unit support. Responses included 18 of 74 (24%) 
treated with ATG alone, 20 of 42 (48%) treated with ATG_CsA, and 1 of 13 (8%) treated with 
CsA. Median response duration was 3 years (3 months to 10 years), and median survival in 
the cohort was 10,5 years. Notably, factors affecting response were younger age ( 60), HLA-
DR15 positivity, and use of combination ATG+CsA. There was no association of response 
with pretreatment marrow cellularity, paroxysmal nocturnal hemoglobinuria clone, or 
absolute neutrophil count. Furthermore, a multivariate analysis of the IST-treated group 
compared with results from a control group of 816 patients with MDS from the International 
Myelodysplasia Risk Analysis Workshop database showed that survival was improved in 
younger patients, those treated with IST, and those with low/intermediate IPSS risk scores. 
The role of IST in MDS treatment remains enigmatic, and the serious toxicities that can be 
encountered with its infusion and long-term immunosuppressive effects have properly led 
to hesitation to its use in community and academic practice. However, in a manner similar 
to the rigorous selection of patients for transplantation, appropriate selection of patients for 
IST affords some the opportunity for prolonged responses without the requirement for 
repeated maintenance chemotherapy (such as AZA or decitabine). IST should be considered 
instead of a hypomethylating agent for previously untreated, younger patients with MDS 
with low or Int-1 risk disease with HLADR15. 
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Predictors of responsiveness are younger age, HLA-DR15 type, the interval between first 
transfusion and starting of immunosuppressive treatment. (Sloand et al., 2008; Barrett et 
al., 2006). 
Passweg et al. reported open-label randomized phase III trial on patients with MDS 
randomly assigned to 15 mg/kg of horse ATG for 5 days and oral CSA for 180 days 
(ATG+CSA) (45 patients) or best supportive care (43 patients), stratified by treatment center 
and International Prognostic Scoring System (IPSS) risk score. Primary end point was best 
hematologic response at 6 months. This trial demonstrated that ATG+CSA treatment seems 
to be associated with hematologic response in a subset of patients without apparent impact 
on transformation free survival and OS (Passweg et al., 2011). 
Because of the toxicities associated with ATG/CsA, an alternative regimen with 
alemtuzumab in MDS was investigated (Sloand et al., 2010). It was a nonrandomized, off-
label, pilot, phase I/II study of alemtuzumab monotherapy in patients with MDS who were 
judged likely to respond to immunosuppressive treatment based on the following criteria: 
HLA-DR15-negative patients whose age plus the number of months of RBC transfusion 
dependence (RCTD) was less than 58; and HLA-DR15-positive patients whose age plus 
RCTD was less than 72. Thirty-two patients were enrolled they received alemtuzumab 10 
mg/d intravenously for 10 days. Primary end points were hematologic responses at 3, 6, 
and 12 months after alemtuzumab. Seventeen (77%) of 22 evaluable intermediate-1 patients 
and four (57%) of seven evaluable intermediate-2 patients responded to treatment with a 
median time to response of 3 months. Four of seven evaluable responders with cytogenetic 
abnormalities before treatment had normal cytogenetics by 1 year after treatment. Five 
(56%) of nine responding patients evaluable at 12 months had normal blood counts, and 
seven (78%) of nine patients were transfusion independent. Alemtuzumab seems to be safe 
and active in MDS and may be an attractive alternative to ATG in selected patients likely to 
respond to IST. 
9.8 Intensive chemotherapy 
About 25 % of patients with newly diagnosed MDS and 15-20 % of patients with established 
MDS have higher risk disease. These patients should be treated immediately, given the high 
likelihood of transformation to AML or death within 1.5 years. One of the treatment options 
is intensive chemotherapy (Bello et al., 2010; Gergis & Wissa, 2010). 
Intensive chemotherapy means some kind of acute leukemia protocol. One of them is the 
FLAG-Ida regimen. The combination of fludarabine, high dose cytarabine and granulocyte 
colony stimulating factor (FLAG) with idarubicin. According to a single centre experience 
treated a total of 105 patients over a 4-year period with 59% achieving a complete remission. 
For patients responding to FLAG - Ida, the median event-free survival was 11 months at 5 
years. Such patients proceeded either to further chemotherapy or a haematopoietic stem cell 
transplant (HSCT). The median EFS (13 months vs. 8 months) and projected 5-year survival 
(37% vs. 13%) of patients undergoing HSCT was significantly better than those who did not. 
The regimens were well tolerated, with the majority of patients experiencing grade 1 or less 
non-haematological toxicity (mainly nausea and vomiting). The median time to neutrophil 
and platelet recovery was 28 and 31 day, respectively. There was a 17% incidence of 
treatment-related deaths, of which 39% was caused by invasive aspergillus infection (Virchis 
et al., 2004). 
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To date, no prospective randomized study has evaluated hypomethylating agents against 
intensive chemotherapy. Proponents of hypomethylating agents argue that they have a 
lower toxicity profile, allowing patients to receive therapy on an outpatient basis, and that 
the lower complete response rates do not necessarily translate into lower survival rates. This 
may be particularly relevant for older MDS patients, who are at higher risk of morbidity 
from intensive chemotherapy. (Scott & Estey, 2008). 
9.9 Autologous stem cell transplantation 
Intensive chemotherapy with AML-like schedules followed by autologous stem cell 
transplantation may provide an alternative option for patients lacking a suitable donor. 
Intensive chemotherapy results in complete remission rates of 15-65%. The median 
remission duration without stem cell transplantation is usually short due to a high incidence 
of early relapses. In view of the high relapse rate after chemotherapy alone transplantation 
with autologous stem cells after remission induction and consolidation chemotherapy has 
been applied in various clinical studies. 
Autologous SCT has been extremely investigated in MDS. It is limited to patients who have 
achieved a CR, can be harvested, and are candidates for the procedure. Autologous SCT 
after successful induction chemotherapy may increase the proportion of long-term 
survivors, thus improving CR duration in some patients with MDS, particularly in younger 
patients in remission. Results for older patients are unsatisfactory. The relapse rate is up to 
75%, with a 2-year probability of disease-free survival of only 25% for patients 40-60 years of 
age (Meletis & Terpos, 2009).  
Autologous peripheral stem cells (PB) result in faster hematopoietic recovery, but may be 
associated with a higher risk of relapse than bone marrow stem cells. In a study comparing 
336 patients transplanted with either bone marrow (BM) (n=104) or PB (n=232). In the 
multivariate Cox model, the event-free survival was not different after PB or BM HSCT. The 
relapse risk after transplantation with stem cells from either source was similar. A 
significant interaction between age and the source of stem cells indicated a more favorable 
potential of autologous PB HSCT in young age groups. As autologous PB and BM HSCT 
result in equivalent outcomes, given the more rapid hematopoietic recovery PB is the 
preferred source of stem cells (de Witte et al., 2006). 
According to the final results of a prospective randomized European Intergroup Trial 
(EORTC-06961) autologous stem cell transplantation does not provide longer survival than 
intensive chemotherapy (de Witte et al., 2010). Therefore, there is very limited enthusiasm 
for the future of autologous SCT in the management of MDS patients. 
Patients with therapy-related MDS/AML had a significantly better disease-free survival 
than did those with the other categories of disease, even after adjustment for confounding 
factors in the Cox model, including interval between diagnosis and transplantation. The 
explanation of this unexpected outcome is not straightforward, but the contribution of 
patients with favorable cytogenetic characteristics might be relevant. We identified eight 
patients with t(8;21) or inversion 16 in an incomplete and ongoing analysis. The 3-year 
disease-free survival of these patients was 57% (de Witte et al., 2007). 
9.10 Allogeneic stem cell transplantation  
Despite the approval of three novel agents for MDS, allogeneic stem cell transplantation 
(alloSCT) is the only curative treatment modality for MDS patients. Allogeneic SCT replaces 
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recipient dysplastic hemopoiesis with healthy donor haemopoiesis and immune system 
with an attendant graft-versus-leukemia (GvL) effect. Its applicability, however, is limited 
by the age of MDS patients, high rates of transplant-related mortality (TRM) and availability 
of a suitable HLA-matched donor. MDS is currently the third most common indication for 
alloSCT. As the disease is most frequent in the older population, the oftener use and 
acceptance of reduced-intensity conditioning (RIC) made the procedure more increased.  
There are several unresolved issues in connection with transplantation. These are the impact 
of pre-transplant tumor debulking, the optimal timing and the transplantation of older 
patients and of those with co-morbidities, and also the issue of post-transplant maintaining 
therapy. The main difficulty is whether can we identify a subset of patients that could 
benefit from early transplantation and also a subset that are anticipated not going to benefit 
from alloSCT. Recent efforts to optimize the curative potential of transplant have focused on 
pretransplant therapy options, the use of predictive models to improve patient selection, 
and transplant modifications using reduced conditioning intensity. 
Dependent upon disease status at the time of transplantation, 30% to 70% of patients can be 
expected to be cured of their disease and survive long term. However, posttransplant 
relapse and graft-versus-host disease (GvHD) remain problems (Bartenstein & Deeg, 2010). 
No prospective randomized controlled trials have directly compared non-transplant 
therapies with SCT for MDS. 
As more than 50% of the patients will fail to benefit from this treatment approach either due 
to TRM or to relapse after transplantation being mindful of patient selection is a main issue 
in decision making.  
9.10.1 Patient selection and decision making 
However, as the majority of patients with MDS are in the seventh or eighth decade of life 
careful consideration must be made to determine whether the patient is a candidate for 
alloSCT. Only approximately 5-10% of higher risk MDS patients are alloSCT candidates.  
Features to consider for alloSCT include the patient’s age and IPSS score (moreover WPSS), 
performance status, co-morbid conditions, availability of a suitable donor (Warlick, 2010; 
Malcovati et al., 2005; Cutler, 2010a,  2010b;).  
The proper assessment of co-morbidities becomes more important. A useful tool is 
hematopoietic cell transplantation co-morbidity index (HCTCI) developed by Sorror et a. 
(Sorror et al., 2005). It has been shown to have a predictive utility on survival also in MDS, 
even in case of patients getting only best supportive care (Zipperer et al., 2009). According to 
a study on 172 MDS patients assessing the impact of co-morbidities on survival and the 
prognostic utility of co-morbidity scores patients with an HCTCI of 0 had a median survival 
time of 68 months, those with an HCTCI of 1 or 2 lived for 34 months, and those with an 
HCTCI of ≥3 survived for 25 months. The HCTCI was able to further subdivide the IPSS 
intermediate-2 and high-risk groups. For patients in the IPSS intermediate-1 and low-risk 
groups, the HCTCI provided no additional prognostic information. The presence of 
pulmonary disease, gastrointestinal tract ulcers, cardiac disorders, and infection were 
independent prognostic factors for survival. HCTCI yielded prognostic information 
independent of the IPSS (Zipperer et al., 2009). 
It is also important to determine whether the patient’s marrow blast count is sufficiently 
low. Data suggest that patients with 5–20% marrow blasts have only 25-28% 5-year overall 
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survival whereas lower risk patients (based on WPSS risk score) do well with alloSCT, with 
a 5-year overall survival of 80% (Alessandrino et al., 2008). 
 
Risk groups Patients NRM 
(%) 
Relapse 
(%) 
OS 
(%) 
RFS 
(%) 
Group I (HCT-CI scores 0–2 and low-
risk diseases) 
Myeloablative 
(n=138) 
11 14 78 75 
Nonmyeloablative 
(n=28) 
4 33 70 63 
Group II (HCT-CI scores 0–2 and 
intermediate and high-risk diseases) 
Myeloablative 
(n=176) 
24 34 51 43 
Nonmyeloablative 
(n=34) 
3 42 57 56 
Group III (HCT-CI scores ≥ 3 and 
low-risk diseases) 
Myeloablative (n=52) 32 27 45 41 
Nonmyeloablative 
(n=19) 
27 37 41 36 
Group IV (HCT-CI scores ≥ 3 and 
intermediate and high-risk diseases) 
Myeloablative (n=86) 46 34 24 20 
Nonmyeloablative 
(n=44) 
29 49 29 23 
Table 3. Two-year NRM, relapse, OS, and RFS incidences among 4 risk groups of 
nonmyeloablative and myeloablative patients with AML or MDS. Donors were either 
related (n=301) or unrelated (n=276) (Sorror et al., 2005). 
9.10.2 Appropriate timing of alloSCT 
The timing of transplantation has always been the most controversial topic of discussion for 
both patients and physicians. The lack of prospective data adds to the doubtfulness in this 
topic. Faced with the uncertainty of transplantation outcomes but the certainty of eventual 
MDS disease progression, decisions are often made based on patient preference. It is clear 
that there is inherent bias in these types of analyses, because the patients included are often 
selected and represent the best transplant candidates.  
To address the shortcomings of these and other biased retrospective analyses, a Markov 
decision model was generated to best understand how treatment decisions would affect 
overall outcome in large cohorts of patients with newly diagnosed MDS (Cutler et al., 2004). 
The decision model was designed to determine if transplantation at the time of initial 
diagnosis, delayed a fixed number of years, or at the time of leukemic transformation was 
the optimal usage strategy for transplantation. Using data from several large, 
nonoverlapping databases, it was demonstrated that the optimal treatment strategy for 
patients with low- and intermediate-1-risk IPSS disease categories was to delay 
transplantation until the time of leukemic progression. Immediate transplantation was 
recommended for patients with high- and intermediate-2-risk IPSS scores (Cutler et al., 
2004). However, a major limitation of this study is that it excluded patients over the age of 
60 and focused solely on myeloablative conditioning.  
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According to the retrospective registry study of de Witte et al. low risk patients benefited by 
early transplantation (within one year after diagnosis) versus more than 12 months from 
diagnosis. Estimated four-year overall survival was 57 % versus 47% (de Witte et al., 2010).  
Beside the IPSS there are also important
 
clinical events such as a new transfusion 
requirement, recurrent
 
infection, or recurrent bleeding episodes that could be considered
 
triggers to move on to transplantation. Transfusion requirement is a very strong predictor of 
the advantage of early transplantation. WPSS incorporates transfusion dependence into the 
score, and enables a dynamic assessment of prognosis during the time-course of the disease. 
WPSS appears more useful than IPSS particularly with respect to patients with low-risk 
disease (Malcovati et al., 2007). Presumably, identification of newer prognostic markers, 
using cytogenetic, immunophenotypic, and molecular techniques will enable further 
improvement in terms of risk stratification and help to clarify the optimal timing for 
transplantation, particularly for patients with low-risk disease. 
9.10.3 Conditioning regimen 
Standard myeloablative conditioning (SMC) results in high treatment-related mortality. 
While a high proportion of patients can achieve long-term disease control when undergoing 
transplantation in early phases of the disease using SMC, transplantation-related deaths 
account for 20% to 30% of treatment failures with such type of conditioning regimens 
(Bearman et al., 1988; de Lima et al., 2004). 
A combination of busulfan (Bu) and cyclophosphamide (Cy) has been used as a standard 
myeloablative regimen for alloSCT. Recent studies postulate that fludarabine (Flu) is a less 
toxic substitute for Cy. Lee et al. compared the two regimens (BuCy vs BuFlu) and showed 
that there was no significant intergroup difference in the time of engraftment, 
nausea/vomiting, acute/chronic graft-versus-host disease, hepatic veno-occlusive disease, 
or hemorrhagic cystitis. Moreover, the 2 groups showed no significant difference in the 
cumulative risk of relapse, event-free survival, or overall survival (Lee et al., 2010; Kindwall-
Keller & Isola, 2009). 
As the vast majority of MDS patients are over 60, using SMC is rarely an option. 
Conditioning regimens with less toxicity for alloSCT are being developed and should be 
available for a higher proportion of patients, particularly those who are elderly. 
It has been well established that for many malignancies the curative potential of allogeneic 
transplantation is, in large part, due to the graft versus malignancy (GVM) effect. This has 
led to the development of less toxic, nonmyeloablative, and reduced intensity 
transplantation regimens that would provide donor cell engraftment and generation of a 
GVM effect. This approach has allowed treatment of older and debilitated patients who 
have been considered ineligible for transplantation using myeloablative regimens (de Lima 
et al., 2004; Gale & Champlin, 1984). 
Reduced-intensity conditioning regimens (these regimens cannot be safely administered 
without stem cell support) usually involve a combination of a purine analog (primarily 
fludarabine) with an alkylating agent (usually melphalan or busulfan). These reduced-
intensity regimens are generally considered to include less than 16 mg/kg busulfan or less 
than 10 Gy total body irradiation (Giralt et al., 1999, 2001). They have been usually 
associated with prompt engraftment of donor cells procured from both HLA-matched 
related and unrelated donors, while the truly nonablative regimens (NMA; can be given 
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routinely without stem cell support, with neutrophil recovery within 28 days) have been 
associated with a varying degree of mixed chimerism and a higher risk of primary and 
secondary graft failures (de Lima et al., 2004).  
However, there are currently no completed prospective randomized controlled studies 
comparing outcomes of RIC to myeloablating conditioning. The best insight into differences 
in outcome comes from large registry-based retrospective studies. These studies 
demonstrate that the use of RIC is associated with a reduction in transplant-related 
mortality but an increased risk of disease relapse. (Horwitz, 2011). 
Based on recent relevant data regarding RIC for transplantation (Laport et al., 2008; 
McClune et al., 2010), patient age and disease status generally dictate the type of 
conditioning to be utilized. For example, those relatively older patients (i.e. >50 or 60 years) 
with <10% marrow blasts would generally be recommended to receive RIC, whereas 
younger patients with a higher marrow blast burden would generally be recommended to 
receive standard conditioning. Regimens assessing novel approaches to RIC for MDS are 
being evaluated (Pagel et al, 2009).  
At MD Anderson Cancer Center a retrospective analysis of transplantation outcomes was 
performed to determine whether in AML and MDS a reduced-intensity conditioning 
regimen would result in lower relapse rates than a truly nonablative regimen. Patients were 
included in this study if they had either AML or high-risk MDS and had undergone an 
alloSCT from an HLA-compatible donor with either a truly nonablative regimen of 
fludarabine, cytarabine (araC), and idarubicin (FAI) or with a RIC regimen with fludarabine 
in combination with melphalan 140 or 180 mg/m2 (FM140 or FM180). FAI was intended to 
be the treatment of choice for older patients (> 55 years) with early disease, having sibling 
donors and who were in remission, and with a high risk of relapse. The 2 doses of 
melphalan were investigated in an attempt to minimize toxicities observed with FM180. The 
lower age limit for participation in the FM studies was 55 years, but younger patients with 
organ dysfunction that made them ineligible for high-dose treatment protocols were also 
eligible. Both related and unrelated donors were allowed. Patients with more advanced 
disease were preferably treated with FM in order to provide higher dose intensity in the 
preparative regimen. The 3-year cumulative incidence of non–relapse-related mortality was 
significantly higher after conditioning with FM than with FAI. Conversely, the 3-year 
cumulative incidence of relapse-related mortality was higher after FAI than after FM. The 
analysis suggests that disease recurrence is more frequent in patients receiving the truly 
nonablative regimen as compared with those receiving the reduced-intensity regimen of 
fludarabine and melphalan. for AML and MDS both cytoreduction of the preparative 
regimen as well as GVM contribute to disease control after allografting with reduced-
intensity or nonablative conditioning regimens. The relative importance of these 
mechanisms, however, may differ with regimens other than those tested here. Truly 
nonablative regimens may be effective in minimal disease states or for diseases highly 
sensitive to GVM effects and may provide a platform for innovative cell therapy approaches 
that may obviate the need for direct cytoreduction of the malignancy (de Lima et al., 2004; 
Virchis et al., 2004). 
There are studies intented to compare outcomes with different conditioning approaches. 
The relative efficacy of 3731 SMC transplant were compared with 1448 RIC/NMA 
procedures performed at 217 centers between 1997 and 2004 on AML/MDS patients. NMA 
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conditioning resulted in inferior disease-free survival (DFS) and OS, but there was no 
difference in DFS and OS between RIC and SMC regimens. Late TRM negates early 
decreases in toxicity with RIC and NMA regimens. These data suggest that higher regimen 
intensity may contribute to optimal survival in patients with AML/MDS, suggesting roles 
for both regimen intensity and graft vs leukemia in these diseases (Luger et al., 2011). 
The addition of alemtuzumab to a RIC regimen dramatically reduces the incidence of acute 
and chronic GVHD in patients with AML and MDS undergoing allogeneic transplantation, 
while TRM, relapse risk, OS and DFS are not affected (van Besien et al., 2009). In another 
study using alemtuzumab-based RIC alloSCT the 3-year non-relapse mortality (NRM) was 
31%, DFS was 41% and overall survival (OS) was 46%. Comorbidity scoring and 
performance status have been suggested as strategies to guide dose adjustment and to 
identify fit 65- to 70-year-old patients who can tolerate myeloablative conditioning while 
those with comorbidities receive less intense regimens. HCT-CI was found to be an 
independent variable affecting 3-year NRM, DFS and OS, indicating that the HCT-CI 
provides an important means of stratifying patients with a high risk of inferior transplant 
outcomes (Lim et al., 2010a; Artz et al., 2006). 
9.10.4 AlloSCT for the elderly 
The median age of diagnosis for patients with MDS is 76 years of age with 86% of patients 
older than 60 years. The NCCN Practice Guidelines, as well as recent expert reviews, 
recommend alloSCT for patients with high-risk MDS without making any age restrictions 
(Greenberg, 2010). However, registry analysis show that few patients older than 65 years are 
actually undergoing this procedure. 
There are no randomized controlled clinical trials evaluating the role of alloSCT for the 
treatment of elderly (> 60 years old) patients with intermediate- to high-risk MDS. The 
highest level of evidence is prospective cohort studies.  
Two studies address the question of age and outcomes after transplantation. 
Lim et al. recently published the results of their retrospective survey. Transplant outcomes 
of 1333 patients with MDS older than 50 years were reported to the European Group for 
Bone Marrow Transplant. The median age was 56 (range, 50 to 74) with 34% of patients 
being older than 60 years, 52% having advanced disease at the time of transplant and 62% 
receiving a RIC regimen. Overall survival for the whole group was 31% at 4 years, with 63% 
of patients dying of nonrelapse causes. The nonrelapse mortality rate was 36% at 4 years 
with no significant difference demonstrated in patients older or younger than 60 years. 
Patients receiving a myeloablative conditioning regimen had a higher risk of transplant-
related mortality than those receiving an RIC regimen (44% v 32%). Relapse rates were 
higher in patients receiving RIC regimens than those receiving myeloablative conditioning 
(41% v 33%). In their multivariate analysis, age was not a significant factor for clinical 
outcomes of relapse or survival. Significant factors associated with nonrelapse mortality 
included type of conditioning, advanced disease at transplantation, and donor type. The 4-
year overall survival estimate was not significantly different between those < 60 years old 
and those > 60 years old. However, relapse rate was increased in the > 60-year-old cohort 
(32% vs 41%). Finally, relapse rate and survival were significantly affected by poor-risk 
cytogenetics (Lim, et al., 2010b). 
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McClune et al. included 535 MDS patients and 545 AML patients
 
in first complete remission 
 
registered with the Center for International Blood and Marrow
 
Transplant Research from 
1995 to 2005. All transplants were
 
(RIC or nonmyeloablative (NMA)
 
conditioning, in 
contrast to the prior study. Thirty-four percent
 
of MDS patients and 36% of AML patients 
were > 60 years old.
 
In both the MDS and AML cohorts, age did not significantly affect
 
nonrelapse mortality, disease-free survival, or overall survival. Long-term disease control
 
was seen in about one-third of MDS patients independent of age,
 
supporting the curative 
potential of SCT for patients with MDS
 
over the age of 60 (McClune et al., 2010). 
Castagna et al. carried out a retrospective study of 63 patients >60 years with hematological 
malignancies and treated with RIC and alloSCT. Only the occurrence of aGVHD affected the 
TRM and OS. Acute GVHD is the main cause of TRM and more efforts should be made to 
reduce its incidence without sacrificing graft vs tumor effect (Castagna et al., 2010).  
Umbilical cord blood (UCB) is feasible as an alternative donor source for RIC alloSCT 
among older patients with MDS who do not have suitable HLA-matched sibling donors 
(MSD). Majhail et al. compared outcomes of allo-SCT, using MSD or UCB among older 
patients (age over 55 years) with AML or MDS. All patients received a RIC regimen 
consisting of cyclophosphamid, fludarabine and 200 cGy TBI. Median age at alloSCT was 63 
years for MSD and 61 years for UCB recipients. On multivariate analysis, donor source 
(MSD vs UCB) did not impact risks of OS, leukemia-free survival and relapse or treatment-
related mortality (Majhail et al., 2011). 
By means of the WPSS the impact of regular transfusion requirement (defined as requiring 
at least one transfusion every 8 weeks in a 4-month period) can be implicated into the risk 
stratification and those low-risk patients can be identified who can benefit of allo-SCT. 
Regular transfusion requirement is given the same regression weight as progressing to a 
higher cytogenetic risk group (Malcovati et al., 2007).  
Based on the available evidence, transplantation for MDS in patients aged 60 or older is the 
only available curative therapy, but its benefit in terms of OS has not been demonstrated in 
randomized controlled trials. Careful patient selection may improve the results (Giralt et al., 
2011; Ria et al,. 2009; Alatrash et al., 2011). 
9.10.5 The issue of the stem cell source and donor selection 
The patients with MDS who received peripheral blood stem cells (PBSC) had a faster 
engraftment and a lower relapse rate, resulting in improved DFS rates, than patients who 
received bone marrow stem cells (Guardiola et al., 2002). There is a shifting tendency 
towards to use PBSC rather than bone marrow stem cells. 
Umbilical cord blood has increased access to hematopoietic cell transplantation (HCT) for 
patients without HLA-matched sibling donors (MSD).  
A study was carried out through the Eurocord and European Group for Blood and 
Marrow Transplantation (EBMT) registries by Robin et al., aiming to evaluate the 
outcomes and risk factors in adult patients who underwent single or double unrelated 
cord blood transplantation (UCBT) for myelodysplastic syndrome (MDS) or secondary 
acute myeloblastic leukemia (sAML). A total of 180 adults with MDS (n=39) or sAML 
(n=69) were analyzed. Median age was 43 (18-72) years. In all, 77 patients (71%) received a 
single UCBT. Myeloablative conditioning regimen (MAC) was given to 57 (53%) patients. 
A 2-year non-relapse mortality (NRM) was significantly higher after MAC (62 vs 34). A 2-
year DFS and overall survival (OS) were 30 and 34%, respectively. In multivariate 
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analysis, patients with high-risk disease (blasts >5% and International Prognostic scoring 
system (IPSS) intermediate-2 or high in MDS) had significant poorer DFS. In spite of high 
NRM, these data indicate that UCBT is an acceptable alternative option to treat adults 
with high-risk MDS or sAML, without a suitable human leukocyte antigen (HLA)-
matched donor (Robin et al., 2011). 
The rate of related versus unrelated donor is also changing. The percentage of older patients 
who are receiving unrelated donor transplants is increasing (Karanes et al., 2008). 
A study compared allogeneic sibling-matched SCT data in MDS patients ≤60 years old to 
clinical outcomes of age-matched non-treated comparable stage MDS patients. Markov 
decision-making statistical analysis indicated that higher risk IPSS patients ≤60 years old 
should proceed to such human leucocyte antigen (HLA) identical sibling transplants at 
diagnosis, whereas for those lower risk MDS patients, delaying transplantation for several 
years and prior to disease progression would be beneficial (Cutler et al., 2004).  
According to newer studies minor HLA disparity in unrelated compared to related donors 
could have a significant impact on transplant outcomes. To assess whether use of unrelated 
donors (URD) engenders more potent graft versus leukaemia effect in RIC alloSCT 
compared to matched related donors (MRD), a retrospective study has been performed 
Dana-Farber Cancer Institute on patients with different haematological malignancies 
including 66 MDS patients (Ho et al., 2010). Patients received uniformly fludarabine and 
intravenous busulfan conditioning, and GVHD prophylaxis with tacrolimus/mini-
methroxate (mini-MTX) or tacrolimus/sirolimus ± mini-MTX. URD was associated with a 
lower risk of relapse (52% versus 65%). 
9.10.6 Reducing relapse rate 
The most important factors for TRM are age, co-morbidities, donor selection and intensity of 
the conditioning regimen. A careful donor selection and an appropriate choice of 
conditioning regimen will significantly reduce TRM. 
On the other hand preferring RIC as preparative regimen, the incidence of relapse will be 
higher. So effords are made to reduce relapse rate. Either improving of the pretransplant 
remission status or by using post-transplant strategies, such as maintenance or consolidation 
therapies can play a role in reducing the risk of relapse (Kröger, 2008). 
In addition to age, the cytogenetic risk score remained an independent prognostic factor for 
relapse. Lenalidomide has shown activity in terms of resolution of chromosomal 
abnormalities, especially in isolated 5q- but also in complex abnormalities involving 5q-. 
There are also some observations that MDS patients with poor cytogenetic abnormalities 
such as monosomy 7 may benefit from hypomethylating agents (Raj et al., 2007). 
Besides improving pretransplant status of patients with MDS by inducing clinical and 
cytogenetic remission, further approaches to reduce the risk of relapse after alloSCT involve 
post-transplant modifications. 
Donor lymphocyte infusion (DLI) can induce durable remission in relapsing patients with 
hematological malignancies after alloSCT. However, the experience of DLI in patients with 
MDS is limited. and the role of it is unclear. In Fred Hutchinson Cancer Research Center, 
Washington 16 patients treated with DLI for relapsed MDS after HCT between 1993 and 
2004. CR with resolution of cytopenias and prior disease markers occurred in 3 of 14 
patients who could be evaluated. Two patients survived without MDS for 68 and 65 months 
after DLI, respectively, but died with pneumonia. Grades II-IV acute GVHD and chronic 
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GVHD occurred after DLI in 6 (43%) and 5 (36%) patients, respectively. All three responders 
developed grades III-IV acute GVHD and extensive chronic GVHD after DLI. This result 
refers that DLI can result in CR in some patients with relapsed MDS after transplant, but 
long-term survival is infrequent (Campregher et al., 2007). Azacitidine combined with DLI 
for relapsed patients may also result remission (Czibere et al., 2010). 
Maintenance therapy with azacitidine is another option. Low dose azacitidine (at 32 mg/m2) 
given for 5 days is safe and can be administered after allogeneic transplant for at least 4 
cycles to heavily pretreated AML/MDS patients. The trial also suggested that this treatment 
may prolong event-free and overall survival, and that more cycles may be associated with 
greater benefit (de Lima et al., 2010). 
9.10.7 Treatment of relapse 
Standard induction chemotherapy may be used for re-induction. The tolerability and 
potential of low dose azacitidine for treatment of relapsed MDS is supported by a Phase I 
trial (de Lima et al., 2010). 
Immunotherapeutic strategies for example peptide vaccination targeting leukemia-
associated antigens, such as the Wilm’s Tumor protein (WT1) (Keilholz et al., 2009) and 
whole cell leukemia vaccination with CD80 and IL-2 genetically modified leukemic blasts 
are currently the subjects of Phase I clinical trial (Ingram et al., 2009). 
9.10.8 The effect of iron oveload on the post-tranplantation survival 
Pre-transplantation transfusion history and serum ferritin have significant prognostic value 
in patients with myelodysplastic syndrome undergoing myeloablative allogeneic stem cell 
transplantation, inducing a significant increase of non-relapse mortality. An elevated serum 
ferritin (1000 g/L) has been associated with reduced OS and increased risk of infection 
following HSCT. Given that ferritin is an acute phase reactant, the elevated ferritin serum 
level alone does not considered to be a satisfactory marker of iron overload. Other 
biomarkers of body iron load should be taken into account to estimate the effect of iron 
overload on the post-transplantation survival (Pullarkat, 2010). These results indicate that 
transfusion history should be considered in transplantation decision-making in patients 
with myelodysplastic syndrome. Outcome was significantly worse in subjects receiving 
more than 20 red cell units. 
Elevated pre-transplantation liver iron content estimated by magnetic resonance imaging 
(MRI) is significantly associated with inferior post-transplantation survival. There is a strong 
correlation between pre-transplantation serum ferritin level and liver iron content which 
was mostly dependent on prior transfusion history (Armand).  
9.11 New agents 
The past several years have brought exciting new treatments strategies for MDS. However, 
despite the huge progress, no curative therapy does exist exclusive of alloSCT nowadays. 
Furthermore, cure is not necessarily essential in the presence of drug therapy that can 
effectively control disease symptoms and prevent disease-related mortality (Tefferi, 2008; 
Rajkumar, 2008). Since the knowledge of molecular genetics in AML and MDS has 
expanded recently, targeted therapeutics should offer new possibilities for advancement 
(Bryan et al., 2010).  
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The nucleoside analog clofarabine, and the alkylating agent cloretazine are now being 
tested. There are several clinical trials using new agents that act at a number of different 
levels. There are new agents with new therapeutic targets, for example tyrosine kinase 
inhibitors (FLT3 inhibitors), farnesyl-transferase inhibitors (Braun & Fenaux, 2008), which 
are thought to target mutant ras activity, agents with c-jun modificating effect, MAP-kinase 
inhibitors, histone deacetylase inhibitors, which cause epigenetic alterations. 
Using combination of drugs with different and new mechanism of action may also be a 
novel approach. Azacitidine in combination with histone deacetylase inhibitors might offer 
better efficacy by modulating the methylation and acetylation states of silenced genes. 
Silverman, 2009, Leuk res 
Single-agent tipifarnib (a farnesyltransferase inhibitor) in high-risk MDS patients achieves 
responses comparable to those of standard epigenetic therapies, including hypomethylating 
agents, and for this reason, farnesyltransferase inhibitors deserve further in MDS. (Braun & 
Fenaux, 2008; Grant, 2009). 
10. Recommendations for treating lower risk (IPSS low, intermediate-1 or 
WPSS very low, low and Intermediate) MDS patients 
Patients with del(5q) chromosomal abnormalities and symptomatic anaemia should receive 
lenalidomide.  
Other patientswith symptomatic anaemia with EPO level  500 mU/ml, should be treated 
with recombinant human EPO or darbepoetin with or without granulocyte-colony 
stimulatin factor (G-CSF). Non-responders should be considered for treatment with 
azacitidine, decitabine or lenalidomide.  
Those anaemic patients with EPO levels  500 mU/ml should be evaluated to determine 
whether they have a good probability of responding to immunosuppressive therapy. For 
those with low probability treatment with azacitidine, decitabine or lenalidomide should be 
recommended. 
Non-responders and those with severe cytopenias participation in a clinical trial, or allo-SCT 
should be an option. 
11. Recommendations for treating higher risk (IPSS Intermediate-2, high-risk 
or WPSS high, very high) MDS patients 
Treatment recommendations for higher risk patients depend on whether they are candidate 
for intensive therapy. Decision should be made by considering the patient’s age, co-
morbidities, physiosocial status and also the patient’s preference and the availability of a 
suitable donor. 
For eligible patients the first choice regarding the donor source has remained an HLA-
matched sibling though results with HLA-matched unrelated donors have improved to a 
similar level. 
Patients older than 55-60 years, particularly those with less than 10 % marrow myeloblasts, 
would be conditioning with RIC. Patients with high blast count pretransplant debulking 
therapy is generally needed. Younger patients, regardless of marrow blast burden, will 
generally receive high dose conditioning.  
For patients eligible for intensive therapy lacking a suitable donor using an intensive 
induction chemotherapy should be recommended. 
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For higher risk patients who are not candidate for intensive therapy the use of azacitidine, 
decitabine or a participation in a clinical trial should be considered. 
Good supportive care should be given to every MDS patients. This may be the only therapy 
for those with adverse clinical features or disease progression despite antitumor therapy. 
12. Conclusion 
Ten years ago, there was little to offer MDS patients other than transfusion support, but 
since then, the approach to treating patients with MDS has undergone a progress. New 
therapeutic options have added to the armamentarium of MDS treatments.  
Historically, treatment goals have varied based on patient risk category, with modification 
of disease reserved for patients in the higher-risk population and response rates being a 
primary endpoint. In the light of recent data the treatment paradigm should be reevaluated 
to focus on prolonging time to leukemic transformation and extending survival while 
improving quality of life. Lenalidomide can modify disease activity, the methyltransferase 
inhibitors have the ability to prolong survival. These are shifting the focus away from 
response rates alone. Azacitidine has demonstrated a sustained impact on overall survival. 
In addition, data suggest that treatment with these therapeutics in patients with lower-risk 
disease may further extend survival by altering the biology of MDS. The new treatment 
paradigm should aim for prolonging leukemic-free transformation and extending survival 
while optimizing quality of life and maintaining hematologic and cytogenetic response. 
The results of stem cell transplantation for MDS continue to improve together with the 
outlook of patients afflicted with myelodysplasia. 
The incidence of MDS is increasing parallely with the increase of the average age of the 
population. That gives a particular importance to the development of MDS therapy has 
taken place in the last decade. In the close future some more possible progress are expected. 
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